2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression
CA 2298737 A1 · Owner: Suthanthiran, Manikkam · Inventors: Suthanthiran, Manikkam; Hojo, Minoru
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a method for reducing formation or progression of neoplasms associated with immunosuppressive therapy in a mammal the method, comprising treating the mammal with an effective amount of a TGF-.beta. antagonist. Also, provided are compositions comprising a TGF-.beta. antagonist and an immunosuppressive, agent such as cyclosporin or FK506. The TGF-.beta. antagonists of the invention include, proteins and polypeptides that bind TGF-.beta. receptors anti-TGF-.beta. , antibodies, TGF-.beta. receptors and fragments thereof. In another aspect the invention provides methods for, identifying compounds capable of inhibiting the formation or proliferation of tumors in a, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 10, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.